Announcements
- Supernus Provides Regulatory Update for SPN-830
- Supernus to Participate in Two Upcoming Investor Conferences
- Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
- Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
- Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
- Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
- Supernus Announces Third Quarter 2023 Financial Results
- Supernus to Participate in the Jefferies London Healthcare Conference
- Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
- Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.99 |
---|---|
High | 21.99 |
Low | 21.99 |
Bid | 21.87 |
Offer | 22.08 |
Previous close | 21.99 |
Average volume | -- |
---|---|
Shares outstanding | 54.73m |
Free float | 51.93m |
P/E (TTM) | 1,143.98 |
Market cap | 1.59bn USD |
EPS (TTM) | -0.0152 USD |
Data delayed at least 15 minutes, as of Dec 29 2020.
More ▼